



Our Products | UCB



























Notice about cookies
This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.


Accept
Close











Top of this page

Skip navigation, go straight to the content





UCB - Inspired by patients. Driven by science.
Menu



Our Company

About usKey factsHistoryManagementCorporate Societal ResponsibilityPartneringSuppliersFundingDisclosure of payments



Disease Areas

Disease areas



Our Science

Our sciencePipelineOur clinical studies




UCB Worldwide

                    Search
                
                    Login
                


Our Products

Products



Newsroom

OverviewPress ReleasesUCB StoriesStory videosResourcesContact



Patients

Patient ProgrammesLife storiesSupport toolsClinical Trials



Investors

OverviewOur equity storyUCB financialsUCB GovernanceOur shareholdersDownload centerIR team





FOLLOW US ON

Facebook
Twitter
YouTube
LinkedIn
RSS



Careers
Contact us


                © 2007 – 2017 UCB S.A., Belgium. All rights reserved.
            





















Our Company
About us
Key facts
History
Management
Corporate Societal Responsibility
Reporting
Patients
Environment
CSR Fund

Partnering
Suppliers
Australia
Austria
Belgium
Brazil
Bulgaria
Canada
China
Czech Republic
Denmark
Finland
France
Germany
Greece
Hong Kong
Hungary
Japan
India
Ireland
Italy
Korea
Luxembourg
Malaysia
Mexico
Netherlands
Norway
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Spain
Sweden
Switzerland
Taiwan
Thailand
Turkey
UK
USA
Requisition to Pay Process
Our Team
Become our supplier

Funding
USA
Other countries

Disclosure of payments
Denmark
Belgium
Finland
Sweden
Hungary
Italy
Netherlands
Ukraine
Ireland
Norway
Romania

Disease Areas
Disease areas

Our Science
Our science
Pipeline
Our clinical studies

Our Products
Products

Newsroom
Overview
Press Releases
UCB Stories
Story videos
UCB Stories 5
December 2016
October 2016
UCB Stories 4

Resources
Contact

Healthcare Professionals
HCP Overview
How can I prevent, limit and manage Impulse Control disorders (ICDs) in people living with Parkinson's disease?

Patients
Patient Programmes
Life stories
Support tools
Clinical Trials

Investors
Overview
Our equity story
UCB financials
UCB Governance
Our shareholders
Shareholders meeting 2012
Shareholders meeting 2013
Shareholders meeting 2014
Shareholders meeting 2016

Download center
IR team

Careers
Applying to UCB


Search






Healthcare Professionals
HCP Overview
How can I prevent, limit and manage Impulse Control disorders (ICDs) in people living with Parkinson's disease?

Patients
Patient Programmes
Life stories
Support tools
Clinical Trials

Investors
Overview
Our equity story
UCB financials
UCB Governance
Our shareholders
Shareholders meeting 2012
Shareholders meeting 2013
Shareholders meeting 2014
Shareholders meeting 2016

Download center
IR team

Careers
Applying to UCBFacebookTwitterYouTubeLinkedInRSS


Scroll down to discover UCB


Mobile Menu
Search
UCB - Inspired by patients. Driven by science.



Products 







Our Products
•
                                                                            Products                                    




ProductsUCB's medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.







NEUROLOGY










 
 Briviact (brivaracetam)EpilepsyVimpat (lacosamide)EpilepsyKeppra (levetiracetam)EpilepsyNeupro (rotigotine)Parkinson's diseaseNeupro (rotigotine)Restless Legs Syndrome







IMMUNOLOGY








 Ankylosing spondylitis Axial spondyloarthritis Crohn's disease Psoriatic arthritis Rheumatoid arthritis 






                			 
                		






OTHER PRODUCTS










 
 Nootropil (piracetam)Memory problemsXyrem (sodium oxybate)NarcolepsyXyzal (levocetirizine)AllergiesZyrtec (cetirizine)Allergies








                				 
                			

IMPORTANT NOTEFor patients: if you wish to report an adverse event related to one of our products, please contact your healthcare provider. In addition you can contact us using the webform available here.For healthcare professionals: if you wish to report an adverse event related to one of our products, please follow the current regulatory procedure in force in your country or contact us using the webform available here.



                			 
                		






                		 
                		


 



Legal notice
Privacy Policy
Cookie Policy
Sitemap
Contact Us
UCB Worldwide


        © 2007 - 2017 UCB S.A., Belgium. All rights reserved
    

                Last updated on: March, 02, 2017    





















UCB S.A. - Product Pipeline Review - 2016























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
UCB S.A. - Product Pipeline Review - 2016









 


  UCB S.A. - Product Pipeline Review - 2016


WGR469329
20 
                  April, 2016 
Global
91 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





UCB S.A. - Product Pipeline Review - 2016
Summary
Global Markets Direct’s, ‘UCB S.A. - Product Pipeline Review - 2016’, provides an overview of the UCB S.A.’s pharmaceutical research and development focus. 
The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.
- The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses UCB S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features UCB S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate UCB S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for UCB S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding UCB S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
UCB S.A. Snapshot 6
UCB S.A. Overview 6
Key Information 6
Key Facts 6
UCB S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
UCB S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
UCB S.A. - Pipeline Products Glance 16
UCB S.A. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
UCB S.A. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
UCB S.A. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
UCB S.A. - Drug Profiles 22
brivaracetam 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
certolizumab pegol 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
lacosamide 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
levetiracetam 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotigotine ER 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
bimekizumab 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
seletalisib 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
UCB-0942 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
UCB-7665 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dapirolizumab pegol 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
UCB-4144 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
UCB-6673 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Antibodies for Cancer, Immunology and Inflammation 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antibody to Inhibit Transglutaminase 2 for Fibrosis 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Inhibit Kinase for Neurodegenerative Diseases 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
UCB S.A. - Pipeline Analysis 59
UCB S.A. - Pipeline Products by Target 59
UCB S.A. - Pipeline Products by Route of Administration 61
UCB S.A. - Pipeline Products by Molecule Type 62
UCB S.A. - Pipeline Products by Mechanism of Action 63
UCB S.A. - Recent Pipeline Updates 65
UCB S.A. - Dormant Projects 81
UCB S.A. - Discontinued Pipeline Products 82
Discontinued Pipeline Product Profiles 82
CDP-323 82
CDP-435 82
CDP-484 82
lacosamide 82
seletracetam 83
UCB-2892 83
UCB S.A. - Company Statement 84
UCB S.A. - Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91
List of Tables
UCB S.A., Key Information 6
UCB S.A., Key Facts 6
UCB S.A. - Pipeline by Indication, 2016 8
UCB S.A. - Pipeline by Stage of Development, 2016 10
UCB S.A. - Monotherapy Products in Pipeline, 2016 11
UCB S.A. - Partnered Products in Pipeline, 2016 12
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016 13
UCB S.A. - Out-Licensed Products in Pipeline, 2016 14
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
UCB S.A. - Pre-Registration, 2016 16
UCB S.A. - Phase III, 2016 17
UCB S.A. - Phase II, 2016 18
UCB S.A. - Phase I, 2016 19
UCB S.A. - Preclinical, 2016 20
UCB S.A. - Discovery, 2016 21
UCB S.A. - Pipeline by Target, 2016 59
UCB S.A. - Pipeline by Route of Administration, 2016 61
UCB S.A. - Pipeline by Molecule Type, 2016 62
UCB S.A. - Pipeline Products by Mechanism of Action, 2016 64
UCB S.A. - Recent Pipeline Updates, 2016 65
UCB S.A. - Dormant Developmental Projects,2016 81
UCB S.A. - Discontinued Pipeline Products, 2016 82
UCB S.A., Subsidiaries 86
List of Figures
UCB S.A. - Pipeline by Top 10 Indication, 2016 8
UCB S.A. - Pipeline by Stage of Development, 2016 10
UCB S.A. - Monotherapy Products in Pipeline, 2016 11
UCB S.A. - Partnered Products in Pipeline, 2016 12
UCB S.A. - Out-Licensed Products in Pipeline, 2016 14
UCB S.A. - Pipeline by Top 10 Target, 2016 59
UCB S.A. - Pipeline by Route of Administration, 2016 61
UCB S.A. - Pipeline by Molecule Type, 2016 62
UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 63







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        


                        1-5 User PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,154.25
   


  1-5 User PDF 
  
 
  2,308.50
  

 
  Enterprise PDF 
  
 
  3,462.75
  





  1-user PDF
  
 
    1,286.40
   


  1-5 User PDF 
  
 
  2,572.80
  

 
  Enterprise PDF 
  
 
  3,859.20
  





  1-user PDF
  
 
    166,735.50
   


  1-5 User PDF 
  
 
  333,471.00
  

 
  Enterprise PDF 
  
 
  500,206.50
  





  1-user PDF
  
 
    96,690.00
   


  1-5 User PDF 
  
 
  193,380.00
  

 
  Enterprise PDF 
  
 
  290,070.00
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 






































UCB S.A. - Product Pipeline Review - 2016































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map











Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies > Pharma Info









Market Research Report
UCB S.A. - Product Pipeline Review - 2016



Published by
Global Markets Direct
Product code
243039


Published
April 20, 2016
Content info
91 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























UCB S.A. - Product Pipeline Review - 2016



Published: April 20, 2016
Content info: 91 Pages














Description

Summary
Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2016', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope

 The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.
 The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries
 The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
 The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
 The report assesses UCB S.A.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
 The report features UCB S.A.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

 Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline
 Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Identify and understand important and diverse types of therapeutics under development for UCB S.A.
 Identify potential new clients or partners in the target demographic
 Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
 Devise corrective measures for pipeline projects by understanding UCB S.A.'s pipeline depth and focus of pipeline therapeutics
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope




Table of Contents
Product Code: GMDHC08030CDB
Table of Contents

Table of Contents 

List of Tables 
List of Figures 

UCB S.A. Snapshot 

UCB S.A. Overview 
Key Information 
Key Facts 

UCB S.A. - Research and Development Overview 

Key Therapeutic Areas 

UCB S.A. - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 
Pipeline Products - Partnered Products 

Partnered Products/Combination Treatment Modalities 

Pipeline Products - Out-Licensed Products 

Out-Licensed Products/Combination Treatment Modalities 


UCB S.A. - Pipeline Products Glance 

UCB S.A. - Late Stage Pipeline Products 

Pre-Registration Products/Combination Treatment Modalities 
Phase III Products/Combination Treatment Modalities 

UCB S.A. - Clinical Stage Pipeline Products 

Phase II Products/Combination Treatment Modalities 
Phase I Products/Combination Treatment Modalities 

UCB S.A. - Early Stage Pipeline Products 

Preclinical Products/Combination Treatment Modalities 
Discovery Products/Combination Treatment Modalities 


UCB S.A. - Drug Profiles 

brivaracetam 

Product Description 
Mechanism of Action 
R&D Progress

certolizumab pegol 

Product Description 
Mechanism of Action 
R&D Progress

lacosamide 

Product Description 
Mechanism of Action 
R&D Progress

levetiracetam 

Product Description 
Mechanism of Action 
R&D Progress

rotigotine ER 

Product Description 
Mechanism of Action 
R&D Progress

bimekizumab 

Product Description 
Mechanism of Action 
R&D Progress

seletalisib 

Product Description 
Mechanism of Action 
R&D Progress

UCB-0942 

Product Description 
Mechanism of Action 
R&D Progress

UCB-7665 

Product Description 
Mechanism of Action 
R&D Progress

dapirolizumab pegol 

Product Description 
Mechanism of Action 
R&D Progress

UCB-4144 

Product Description 
Mechanism of Action 
R&D Progress

UCB-6673 

Product Description 
Mechanism of Action 
R&D Progress

Antibodies for Cancer, Immunology and Inflammation 

Product Description 
Mechanism of Action 
R&D Progress

Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders 

Product Description 
Mechanism of Action 
R&D Progress

Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 

Product Description 
Mechanism of Action 
R&D Progress

Antibody to Inhibit Transglutaminase 2 for Fibrosis 

Product Description 
Mechanism of Action 
R&D Progress

Small Molecules to Inhibit Kinase for Neurodegenerative Diseases 

Product Description 
Mechanism of Action 
R&D Progress


UCB S.A. - Pipeline Analysis 

UCB S.A. - Pipeline Products by Target 
UCB S.A. - Pipeline Products by Route of Administration 
UCB S.A. - Pipeline Products by Molecule Type 
UCB S.A. - Pipeline Products by Mechanism of Action 

UCB S.A. - Recent Pipeline Updates 
UCB S.A. - Dormant Projects 
UCB S.A. - Discontinued Pipeline Products 

Discontinued Pipeline Product Profiles 

CDP-323 
CDP-435 
CDP-484 
lacosamide 
seletracetam 
UCB-2892 


UCB S.A. - Company Statement 
UCB S.A. - Locations And Subsidiaries 

Head Office 
Other Locations & Subsidiaries 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

UCB S.A., Key Information 
UCB S.A., Key Facts 
UCB S.A. - Pipeline by Indication, 2016 
UCB S.A. - Pipeline by Stage of Development, 2016 
UCB S.A. - Monotherapy Products in Pipeline, 2016 
UCB S.A. - Partnered Products in Pipeline, 2016 
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016 
UCB S.A. - Out-Licensed Products in Pipeline, 2016 
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 
UCB S.A. - Pre-Registration, 2016 
UCB S.A. - Phase III, 2016 
UCB S.A. - Phase II, 2016 
UCB S.A. - Phase I, 2016 
UCB S.A. - Preclinical, 2016 
UCB S.A. - Discovery, 2016 
UCB S.A. - Pipeline by Target, 2016 
UCB S.A. - Pipeline by Route of Administration, 2016 
UCB S.A. - Pipeline by Molecule Type, 2016 
UCB S.A. - Pipeline Products by Mechanism of Action, 2016 
UCB S.A. - Recent Pipeline Updates, 2016 
UCB S.A. - Dormant Developmental Projects,2016 
UCB S.A. - Discontinued Pipeline Products, 2016 
UCB S.A., Subsidiaries 

List of Figures

UCB S.A. - Pipeline by Top 10 Indication, 2016 
UCB S.A. - Pipeline by Stage of Development, 2016 
UCB S.A. - Monotherapy Products in Pipeline, 2016 
UCB S.A. - Partnered Products in Pipeline, 2016 
UCB S.A. - Out-Licensed Products in Pipeline, 2016 
UCB S.A. - Pipeline by Top 10 Target, 2016 
UCB S.A. - Pipeline by Route of Administration, 2016 
UCB S.A. - Pipeline by Molecule Type, 2016 
UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports
















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.























UCB S.A. - Product Pipeline Review - 2016 Trends, Statistics, Segment and Forecasts, Market Size, Share Analysis : Market Research Store



















+49 322 210 92714
                                    (GMT OFFICE HOURS)
                                

+1-855-465-4651
                                    (US/CAN TOLL FREE)
                                

+1-386-310-3803
                                    (US OFFICE NO)
                                
































Home
Categories
Become Publisher
News
About Us
Contact Us



























-Select Category-
Consumer Goods
Food & Beverage
Heavy Industry
Life Sciences
Marketing & Market Research
Public Sector
Service Industries
Technology & Media
Semiconductor
Chemical and Materials
Metallurgical
Market Research




Search












Home >> Life Sciences >> Pharmaceuticals


UCB S.A. - Product Pipeline Review - 2016



Published: Apr-2016 | Format: PDF | Global Markets Direct | Number of pages: 91 | Code: MRS - 58497



Report Details
Table Of Content
Inquiry For Buying
Request Sample



UCB S.A. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘UCB S.A. - Product Pipeline Review - 2016’, provides an overview of the UCB S.A.’s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by UCB S.A., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of UCB S.A.
- The report provides overview of UCB S.A. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses UCB S.A.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features UCB S.A.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate UCB S.A.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for UCB S.A.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding UCB S.A.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
UCB S.A. Snapshot 6
UCB S.A. Overview 6
Key Information 6
Key Facts 6
UCB S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
UCB S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
UCB S.A. - Pipeline Products Glance 16
UCB S.A. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
UCB S.A. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
UCB S.A. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
UCB S.A. - Drug Profiles 22
brivaracetam 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
certolizumab pegol 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
lacosamide 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
levetiracetam 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotigotine ER 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
bimekizumab 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
seletalisib 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
UCB-0942 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
UCB-7665 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dapirolizumab pegol 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
UCB-4144 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
UCB-6673 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Antibodies for Cancer, Immunology and Inflammation 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody to Inhibit Fatty Acid-Binding Protein 4 for Diabetes and Metabolic Disorders 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antibody to Inhibit Transglutaminase 2 for Fibrosis 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Inhibit Kinase for Neurodegenerative Diseases 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
UCB S.A. - Pipeline Analysis 59
UCB S.A. - Pipeline Products by Target 59
UCB S.A. - Pipeline Products by Route of Administration 61
UCB S.A. - Pipeline Products by Molecule Type 62
UCB S.A. - Pipeline Products by Mechanism of Action 63
UCB S.A. - Recent Pipeline Updates 65
UCB S.A. - Dormant Projects 81
UCB S.A. - Discontinued Pipeline Products 82
Discontinued Pipeline Product Profiles 82
CDP-323 82
CDP-435 82
CDP-484 82
lacosamide 82
seletracetam 83
UCB-2892 83
UCB S.A. - Company Statement 84
UCB S.A. - Locations And Subsidiaries 86
Head Office 86
Other Locations & Subsidiaries 86
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91 
List of Tables
UCB S.A., Key Information 6
UCB S.A., Key Facts 6
UCB S.A. - Pipeline by Indication, 2016 8
UCB S.A. - Pipeline by Stage of Development, 2016 10
UCB S.A. - Monotherapy Products in Pipeline, 2016 11
UCB S.A. - Partnered Products in Pipeline, 2016 12
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2016 13
UCB S.A. - Out-Licensed Products in Pipeline, 2016 14
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
UCB S.A. - Pre-Registration, 2016 16
UCB S.A. - Phase III, 2016 17
UCB S.A. - Phase II, 2016 18
UCB S.A. - Phase I, 2016 19
UCB S.A. - Preclinical, 2016 20
UCB S.A. - Discovery, 2016 21
UCB S.A. - Pipeline by Target, 2016 59
UCB S.A. - Pipeline by Route of Administration, 2016 61
UCB S.A. - Pipeline by Molecule Type, 2016 62
UCB S.A. - Pipeline Products by Mechanism of Action, 2016 64
UCB S.A. - Recent Pipeline Updates, 2016 65
UCB S.A. - Dormant Developmental Projects,2016 81
UCB S.A. - Discontinued Pipeline Products, 2016 82
UCB S.A., Subsidiaries 86 
List of Figures
UCB S.A. - Pipeline by Top 10 Indication, 2016 8
UCB S.A. - Pipeline by Stage of Development, 2016 10
UCB S.A. - Monotherapy Products in Pipeline, 2016 11
UCB S.A. - Partnered Products in Pipeline, 2016 12
UCB S.A. - Out-Licensed Products in Pipeline, 2016 14
UCB S.A. - Pipeline by Top 10 Target, 2016 59
UCB S.A. - Pipeline by Route of Administration, 2016 61
UCB S.A. - Pipeline by Molecule Type, 2016 62
UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2016 63 

Inquiry For Buying

Please fill your details below, to inquire about this report:
* Indicates required fields






 





Name:






Email:






Phone:






Name of company:






Title/Designation:






Country Name:

-Select Country-
ANDORRA
UNITED ARAB EMIRATES
AFGHANISTAN
ANTIGUA AND BARBUDA
ANGUILLA
ALBANIA
ARMENIA
ANGOLA
ANTARCTICA
ARGENTINA
AMERICAN SAMOA
AUSTRIA
AUSTRALIA
ARUBA
ÅLAND ISLANDS
AZERBAIJAN
BOSNIA AND HERZEGOVINA
BARBADOS
BANGLADESH
BELGIUM
BURKINA FASO
BULGARIA
BAHRAIN
BURUNDI
BENIN
SAINT BARTHÉLEMY
BERMUDA
BRUNEI DARUSSALAM
BOLIVIA, PLURINATIONAL STATE OF
BONAIRE, SINT EUSTATIUS AND SABA
BRAZIL
BAHAMAS
BHUTAN
BOUVET ISLAND
BOTSWANA
BELARUS
BELIZE
CANADA
COCOS (KEELING) ISLANDS
CONGO, THE DEMOCRATIC REPUBLIC OF THE
CENTRAL AFRICAN REPUBLIC
CONGO
SWITZERLAND
CÔTE D'IVOIRE
COOK ISLANDS
CHILE
CAMEROON
CHINA
COLOMBIA
COSTA RICA
CUBA
CAPE VERDE
CURAÇAO
CHRISTMAS ISLAND
CYPRUS
CZECH REPUBLIC
GERMANY
DJIBOUTI
DENMARK
DOMINICA
DOMINICAN REPUBLIC
ALGERIA
ECUADOR
ESTONIA
EGYPT
WESTERN SAHARA
ERITREA
SPAIN
ETHIOPIA
FINLAND
FIJI
FALKLAND ISLANDS (MALVINAS)
MICRONESIA, FEDERATED STATES OF
FAROE ISLANDS
FRANCE
GABON
UNITED KINGDOM
GRENADA
GEORGIA
FRENCH GUIANA
GUERNSEY
GHANA
GIBRALTAR
GREENLAND
GAMBIA
GUINEA
GUADELOUPE
EQUATORIAL GUINEA
GREECE
SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
GUATEMALA
GUAM
GUINEA-BISSAU
GUYANA
HONG KONG
HEARD ISLAND AND MCDONALD ISLANDS
HONDURAS
CROATIA
HAITI
HUNGARY
INDONESIA
IRELAND
ISRAEL
ISLE OF MAN
INDIA
BRITISH INDIAN OCEAN TERRITORY
IRAQ
IRAN, ISLAMIC REPUBLIC OF
ICELAND
ITALY
JERSEY
JAMAICA
JORDAN
JAPAN
KENYA
KYRGYZSTAN
CAMBODIA
KIRIBATI
COMOROS
SAINT KITTS AND NEVIS
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
KOREA, REPUBLIC OF
KUWAIT
CAYMAN ISLANDS
KAZAKHSTAN
LAO PEOPLE'S DEMOCRATIC REPUBLIC
LEBANON
SAINT LUCIA
LIECHTENSTEIN
SRI LANKA
LIBERIA
LESOTHO
LITHUANIA
LUXEMBOURG
LATVIA
LIBYA
MOROCCO
MONACO
MOLDOVA, REPUBLIC OF
MONTENEGRO
SAINT MARTIN (FRENCH PART)
MADAGASCAR
MARSHALL ISLANDS
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF
MALI
MYANMAR
MONGOLIA
MACAO
NORTHERN MARIANA ISLANDS
MARTINIQUE
MAURITANIA
MONTSERRAT
MALTA
MAURITIUS
MALDIVES
MALAWI
MEXICO
MALAYSIA
MOZAMBIQUE
NAMIBIA
NEW CALEDONIA
NIGER
NORFOLK ISLAND
NIGERIA
NICARAGUA
NETHERLANDS
NORWAY
NEPAL
NAURU
NIUE
NEW ZEALAND
OMAN
PANAMA
PERU
FRENCH POLYNESIA
PAPUA NEW GUINEA
PHILIPPINES
PAKISTAN
POLAND
SAINT PIERRE AND MIQUELON
PITCAIRN
PUERTO RICO
PALESTINIAN, STATE OF
PORTUGAL
PALAU
PARAGUAY
QATAR
RÉUNION
ROMANIA
SERBIA
RUSSIAN FEDERATION
RWANDA
SAUDI ARABIA
SOLOMON ISLANDS
SEYCHELLES
SUDAN
SWEDEN
SINGAPORE
SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
SLOVENIA
SVALBARD AND JAN MAYEN
SLOVAKIA
SIERRA LEONE
SAN MARINO
SENEGAL
SOMALIA
SURINAME
SOUTH SUDAN
SAO TOME AND PRINCIPE
EL SALVADOR
SINT MAARTEN (DUTCH PART)
SYRIAN ARAB REPUBLIC
SWAZILAND
TURKS AND CAICOS ISLANDS
CHAD
FRENCH SOUTHERN TERRITORIES
TOGO
THAILAND
TAJIKISTAN
TOKELAU
TIMOR-LESTE
TURKMENISTAN
TUNISIA
TONGA
TURKEY
TRINIDAD AND TOBAGO
TUVALU
TAIWAN, PROVINCE OF CHINA
TANZANIA, UNITED REPUBLIC OF
UKRAINE
UGANDA
UNITED STATES MINOR OUTLYING ISLANDS
UNITED STATES
URUGUAY
UZBEKISTAN
HOLY SEE (VATICAN CITY STATE)
SAINT VINCENT AND THE GRENADINES
VENEZUELA, BOLIVARIAN REPUBLIC OF
VIRGIN ISLANDS, BRITISH
VIRGIN ISLANDS, U.S.
VIET NAM
VANUATU
WALLIS AND FUTUNA
SAMOA
YEMEN
MAYOTTE
SOUTH AFRICA
ZAMBIA
ZIMBABWE





How can we help you?











Refresh



captcha:





 


Submit







Request Sample

Please fill your details below, to receive sample report:
* Indicates required fields






 





Name:






Email:






Phone:






Name of company:






Title/Designation:






Country Name:

-Select Country-
ANDORRA
UNITED ARAB EMIRATES
AFGHANISTAN
ANTIGUA AND BARBUDA
ANGUILLA
ALBANIA
ARMENIA
ANGOLA
ANTARCTICA
ARGENTINA
AMERICAN SAMOA
AUSTRIA
AUSTRALIA
ARUBA
ÅLAND ISLANDS
AZERBAIJAN
BOSNIA AND HERZEGOVINA
BARBADOS
BANGLADESH
BELGIUM
BURKINA FASO
BULGARIA
BAHRAIN
BURUNDI
BENIN
SAINT BARTHÉLEMY
BERMUDA
BRUNEI DARUSSALAM
BOLIVIA, PLURINATIONAL STATE OF
BONAIRE, SINT EUSTATIUS AND SABA
BRAZIL
BAHAMAS
BHUTAN
BOUVET ISLAND
BOTSWANA
BELARUS
BELIZE
CANADA
COCOS (KEELING) ISLANDS
CONGO, THE DEMOCRATIC REPUBLIC OF THE
CENTRAL AFRICAN REPUBLIC
CONGO
SWITZERLAND
CÔTE D'IVOIRE
COOK ISLANDS
CHILE
CAMEROON
CHINA
COLOMBIA
COSTA RICA
CUBA
CAPE VERDE
CURAÇAO
CHRISTMAS ISLAND
CYPRUS
CZECH REPUBLIC
GERMANY
DJIBOUTI
DENMARK
DOMINICA
DOMINICAN REPUBLIC
ALGERIA
ECUADOR
ESTONIA
EGYPT
WESTERN SAHARA
ERITREA
SPAIN
ETHIOPIA
FINLAND
FIJI
FALKLAND ISLANDS (MALVINAS)
MICRONESIA, FEDERATED STATES OF
FAROE ISLANDS
FRANCE
GABON
UNITED KINGDOM
GRENADA
GEORGIA
FRENCH GUIANA
GUERNSEY
GHANA
GIBRALTAR
GREENLAND
GAMBIA
GUINEA
GUADELOUPE
EQUATORIAL GUINEA
GREECE
SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS
GUATEMALA
GUAM
GUINEA-BISSAU
GUYANA
HONG KONG
HEARD ISLAND AND MCDONALD ISLANDS
HONDURAS
CROATIA
HAITI
HUNGARY
INDONESIA
IRELAND
ISRAEL
ISLE OF MAN
INDIA
BRITISH INDIAN OCEAN TERRITORY
IRAQ
IRAN, ISLAMIC REPUBLIC OF
ICELAND
ITALY
JERSEY
JAMAICA
JORDAN
JAPAN
KENYA
KYRGYZSTAN
CAMBODIA
KIRIBATI
COMOROS
SAINT KITTS AND NEVIS
KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF
KOREA, REPUBLIC OF
KUWAIT
CAYMAN ISLANDS
KAZAKHSTAN
LAO PEOPLE'S DEMOCRATIC REPUBLIC
LEBANON
SAINT LUCIA
LIECHTENSTEIN
SRI LANKA
LIBERIA
LESOTHO
LITHUANIA
LUXEMBOURG
LATVIA
LIBYA
MOROCCO
MONACO
MOLDOVA, REPUBLIC OF
MONTENEGRO
SAINT MARTIN (FRENCH PART)
MADAGASCAR
MARSHALL ISLANDS
MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF
MALI
MYANMAR
MONGOLIA
MACAO
NORTHERN MARIANA ISLANDS
MARTINIQUE
MAURITANIA
MONTSERRAT
MALTA
MAURITIUS
MALDIVES
MALAWI
MEXICO
MALAYSIA
MOZAMBIQUE
NAMIBIA
NEW CALEDONIA
NIGER
NORFOLK ISLAND
NIGERIA
NICARAGUA
NETHERLANDS
NORWAY
NEPAL
NAURU
NIUE
NEW ZEALAND
OMAN
PANAMA
PERU
FRENCH POLYNESIA
PAPUA NEW GUINEA
PHILIPPINES
PAKISTAN
POLAND
SAINT PIERRE AND MIQUELON
PITCAIRN
PUERTO RICO
PALESTINIAN, STATE OF
PORTUGAL
PALAU
PARAGUAY
QATAR
RÉUNION
ROMANIA
SERBIA
RUSSIAN FEDERATION
RWANDA
SAUDI ARABIA
SOLOMON ISLANDS
SEYCHELLES
SUDAN
SWEDEN
SINGAPORE
SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA
SLOVENIA
SVALBARD AND JAN MAYEN
SLOVAKIA
SIERRA LEONE
SAN MARINO
SENEGAL
SOMALIA
SURINAME
SOUTH SUDAN
SAO TOME AND PRINCIPE
EL SALVADOR
SINT MAARTEN (DUTCH PART)
SYRIAN ARAB REPUBLIC
SWAZILAND
TURKS AND CAICOS ISLANDS
CHAD
FRENCH SOUTHERN TERRITORIES
TOGO
THAILAND
TAJIKISTAN
TOKELAU
TIMOR-LESTE
TURKMENISTAN
TUNISIA
TONGA
TURKEY
TRINIDAD AND TOBAGO
TUVALU
TAIWAN, PROVINCE OF CHINA
TANZANIA, UNITED REPUBLIC OF
UKRAINE
UGANDA
UNITED STATES MINOR OUTLYING ISLANDS
UNITED STATES
URUGUAY
UZBEKISTAN
HOLY SEE (VATICAN CITY STATE)
SAINT VINCENT AND THE GRENADINES
VENEZUELA, BOLIVARIAN REPUBLIC OF
VIRGIN ISLANDS, BRITISH
VIRGIN ISLANDS, U.S.
VIET NAM
VANUATU
WALLIS AND FUTUNA
SAMOA
YEMEN
MAYOTTE
SOUTH AFRICA
ZAMBIA
ZIMBABWE





How can we help you?











Refresh



captcha:





 


Submit











Related Reports


Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors

Jun-2017 | GBI Research | Pages : 420 | Code : MRS-150344 | 4995
                    
Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Summary In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable. Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemothera Read more




Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 51 | Code : MRS-150325 | 3500
                    
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2017 Summary Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis. Interleukin 7 Recep Read more




78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 47 | Code : MRS-150324 | 3500
                    
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2017 Summary 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are devel Read more




Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 77 | Code : MRS-150323 | 3500
                    
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2017 Summary According to the recently published report 'Survival Motor Neuron Protein - Pipeline Review, H2 2017'; Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Survival Motor Neuron Protein ( Read more




Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 37 | Code : MRS-150322 | 3500
                    
Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and  Read more




Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 30 | Code : MRS-150321 | 3500
                    
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report SerineThreonine Protein Kinase A Raf - Pipeline Review, H2 2017, outlays comprehensive information on the Serin Read more




MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 35 | Code : MRS-150320 | 3500
                    
MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the recently published report 'MAP Kinase Interacting SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2017'; MAP Kinase Interacting Serine/Threonine Protein Kinase 2 (MAP Kinase Signal Integrating Kinase 2 or MKNK2 or EC 2.7.11.1) pipeline Target constitutes close to 9 molecules. Out of which approximately 4 molecu Read more




Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 47 | Code : MRS-150319 | 3500
                    
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphoryla Read more




Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 45 | Code : MRS-150318 | 3500
                    
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2017 Summary Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) pipeline Target constitutes close to 8 molecules. Out of which approximately 5 molecules are developed by  Read more




Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2017

Jul-2017 | Global Markets Direct | Pages : 37 | Code : MRS-150317 | 3500
                    
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Pipeline Review, H2 2017 Summary According to the recently published report 'Protein Glutamine Gamma Glutamyltransferase 2 - Pipeline Review, H2 2017'; Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutaminase or Transglutaminase C or Transglutaminase H or Transglutaminase 2 or TGase C or TGase Read more








Payment Mode




Single User  | $(USD)1500








Multi User | $(USD)3000








Corporate User  | $(USD)4500













Latest Report


2017 Global Non-Slip Epoxy Glass Flake Paint Market Research Report


2017 Global Parking Sensors Market Research Report


2017 Global Nitrogen Oxide Sensor Market Research Report


2017 Global Nuclear Density Gauge Market Research Report


2017 Global Automotive Interior Materials Market Research Report

View More



Latest News


Global Chitosan Market Set for Rapid Growth, To Reach USD 4.74 Billion by 2021

Zion Market Research has published a new report titled Chitosan Market for Water Treatment, Biomed



Development of e-commerce to Reshape Global Mobile Hotspot Router Market

Mobile hotspot is a popular feature on smart phones that provide wireless internet access on many 



Global Carotenoids Market Is Expected To Reach Around USD 1.52 Billion in 2021

Zion Market Research has published a new report titled Carotenoids Market by Type (Astaxanthin, Be



Soaring Demand from Food & Beverages Industry to Act as Prime Driving for Ascorbic Acid Market, Reports Zion Market Research

Ascorbic acid is extensively available in nature, mostly rich in leafy vegetables and fresh fruits



Global Energy Management System (EMS) Market Is Set for a Rapid Growth and is Expected to Reach USD 63,161.5 million by 2021

Zion Market Research has published a new report titled Energy Management System Market (EMS) by So


View More














Single User | $(USD)1500
View Pricing 













Find Help

How to Order
Disclaimer 
FAQs
Return Policy
Sitemap



Our Company

About Us
Terms and Conditions
Privacy Policy



We accept the following payment methods






© 2016 - 2017 Market Research Store - Market Research Reports 
















UCB S.A. - Product Pipeline Review - 2015























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
UCB S.A. - Product Pipeline Review - 2015









 


  UCB S.A. - Product Pipeline Review - 2015


WGR56356
22 
                  April, 2015 
Global
90 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





UCB S.A. - Product Pipeline Review - 2015SummaryGlobal Markets Direct’s, ‘UCB S.A. - Product Pipeline Review - 2015’, provides an overview of the UCB S.A.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of UCB S.A.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the UCB S.A.’s pipeline productsReasons to buy- Evaluate UCB S.A.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of UCB S.A. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the UCB S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 5List of Figures 5UCB S.A. Snapshot 6UCB S.A. Overview 6Key Information 6Key Facts 6UCB S.A. - Research and Development Overview 7Key Therapeutic Areas 7UCB S.A. - Pipeline Review 10Pipeline Products by Stage of Development 10Pipeline Products - Monotherapy 11Pipeline Products - Partnered Products 12Partnered Products/Combination Treatment Modalities 13Pipeline Products - Out-Licensed Products 14Out-Licensed Products/Combination Treatment Modalities 15UCB S.A. - Pipeline Products Glance 16UCB S.A. - Late Stage Pipeline Products 16Pre-Registration Products/Combination Treatment Modalities 16Phase III Products/Combination Treatment Modalities 17UCB S.A. - Clinical Stage Pipeline Products 18Phase II Products/Combination Treatment Modalities 18Phase I Products/Combination Treatment Modalities 19UCB S.A. - Early Stage Pipeline Products 20Preclinical Products/Combination Treatment Modalities 20Discovery Products/Combination Treatment Modalities 21UCB S.A. - Drug Profiles 22brivaracetam 22Product Description 22Mechanism of Action 22R&D Progress 22certolizumab pegol 24Product Description 24Mechanism of Action 24R&D Progress 24levetiracetam 31Product Description 31Mechanism of Action 31R&D Progress 31epratuzumab 34Product Description 34Mechanism of Action 34R&D Progress 34lacosamide 39Product Description 39Mechanism of Action 39R&D Progress 39rotigotine 44Product Description 44Mechanism of Action 44R&D Progress 44bimekizumab 47Product Description 47Mechanism of Action 47R&D Progress 47dapirolizumab pegol 48Product Description 48Mechanism of Action 48R&D Progress 48UCB-0942 50Product Description 50Mechanism of Action 50R&D Progress 50UCB-5857 51Product Description 51Mechanism of Action 51R&D Progress 51UCB-7665 52Product Description 52Mechanism of Action 52R&D Progress 52Antibodies for Cancer, Immunology and Inflammation 53Product Description 53Mechanism of Action 53R&D Progress 53Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 54Product Description 54Mechanism of Action 54R&D Progress 54VR-942 55Product Description 55Mechanism of Action 55R&D Progress 55Antibodies for Diabetes and Metabolic Disorders 56Product Description 56Mechanism of Action 56R&D Progress 56Antibody to Inhibit Transglutaminase 2 for Fibrosis 57Product Description 57Mechanism of Action 57R&D Progress 57UCB S.A. - Pipeline Analysis 58UCB S.A. - Pipeline Products by Target 58UCB S.A. - Pipeline Products by Route of Administration 60UCB S.A. - Pipeline Products by Molecule Type 61UCB S.A. - Pipeline Products by Mechanism of Action 62UCB S.A. - Recent Pipeline Updates 63UCB S.A. - Dormant Projects 79UCB S.A. - Discontinued Pipeline Products 80Discontinued Pipeline Product Profiles 80CDP-323 80CDP-435 80CDP-484 81CDP-860 81lacosamide 81seletracetam 81UCB-2892 81WX-037 82WX-554 82UCB S.A. - Company Statement 83UCB S.A. - Locations And Subsidiaries 84Head Office 84Other Locations & Subsidiaries 84Appendix 89Methodology 89Coverage 89Secondary Research 89Primary Research 89Expert Panel Validation 89Contact Us 89Disclaimer 90List of TablesUCB S.A., Key Information 6UCB S.A., Key Facts 6UCB S.A. - Pipeline by Indication, 2015 9UCB S.A. - Pipeline by Stage of Development, 2015 10UCB S.A. - Monotherapy Products in Pipeline, 2015 11UCB S.A. - Partnered Products in Pipeline, 2015 12UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2015 13UCB S.A. - Out-Licensed Products in Pipeline, 2015 14UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15UCB S.A. - Pre-Registration, 2015 16UCB S.A. - Phase III, 2015 17UCB S.A. - Phase II, 2015 18UCB S.A. - Phase I, 2015 19UCB S.A. - Preclinical, 2015 20UCB S.A. - Discovery, 2015 21UCB S.A. - Pipeline by Target, 2015 59UCB S.A. - Pipeline by Route of Administration, 2015 60UCB S.A. - Pipeline by Molecule Type, 2015 61UCB S.A. - Pipeline Products by Mechanism of Action, 2015 62UCB S.A. - Recent Pipeline Updates, 2015 63UCB S.A. - Dormant Developmental Projects,2015 79UCB S.A. - Discontinued Pipeline Products, 2015 80UCB S.A., Subsidiaries 84List of FiguresUCB S.A. - Pipeline by Top 10 Indication, 2015 8UCB S.A. - Pipeline by Stage of Development, 2015 10UCB S.A. - Monotherapy Products in Pipeline, 2015 11UCB S.A. - Partnered Products in Pipeline, 2015 12UCB S.A. - Out-Licensed Products in Pipeline, 2015 14UCB S.A. - Pipeline by Top 10 Target, 2015 58UCB S.A. - Pipeline by Top 10 Route of Administration, 2015 60UCB S.A. - Pipeline by Top 10 Molecule Type, 2015 61UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 62







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,154.25
   

 
  Site PDF 
  
 
  2,308.50
  

 
  Enterprise PDF 
  
 
  3,462.75
  





  1-user PDF
  
 
    1,286.40
   

 
  Site PDF 
  
 
  2,572.80
  

 
  Enterprise PDF 
  
 
  3,859.20
  





  1-user PDF
  
 
    166,735.50
   

 
  Site PDF 
  
 
  333,471.00
  

 
  Enterprise PDF 
  
 
  500,206.50
  





  1-user PDF
  
 
    96,690.00
   

 
  Site PDF 
  
 
  193,380.00
  

 
  Enterprise PDF 
  
 
  290,070.00
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 





































	Market Report: UCB S.A. - Product Pipeline Review - 2015

















































ABOUT US

• PUBLISHERS
• CONTACT US
• CART




Login | Register















All Industries
Business & Finance
-- Business
-- Financial Services
-- Insurance
-- Marketing
Consumer & Food
-- Beverages
-- Consumer Goods
-- Food
-- Retailing
Healthcare
-- Biotechnology
-- Healthcare
-- Medical Devices
-- Pharmaceuticals
Heavy Industry
-- Construction
-- Energy
-- Manufacturing
-- Materials
-- Transportation
Internet & Media
-- E-Business
-- Internet
-- Media
-- Publishing
Public Sector
-- Defense
-- Education
-- Government
Telecom & Computing
-- Computer Technology
-- Fixed Networks
-- Software
-- Wireless
Company/Country Reports
-- Company Reports
-- Country Reports
-- Regional Reports


 
            













                        Processing...




UCB S.A. - Product Pipeline Review - 2015

     
                        Apr 22, 2015 - Global Markets Direct 
                    
                - 90 pages 
                - USD $1,500 
         





Click here to open the POPUP


                        You've added the following report to your cart:CLOSE








Cart Summary



                                    Total Items: 
                                

                                    SubTotal: 
                                


    









Report Summary


Table of Contents


Companies


Request Details


Related







Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2015', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of UCB S.A.'s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the UCB S.A.'s pipeline productsReasons to buyEvaluate UCB S.A.'s strategic position with total access to detailed information on its product pipelineAssess the growth potential of UCB S.A. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the UCB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues
Table of ContentsTable of ContentsList of TablesList of FiguresUCB S.A. SnapshotUCB S.A. OverviewKey InformationKey FactsUCB S.A. - Research and Development OverviewKey Therapeutic AreasUCB S.A. - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyPipeline Products - Partnered ProductsPartnered Products/Combination Treatment ModalitiesPipeline Products - Out-Licensed ProductsOut-Licensed Products/Combination Treatment ModalitiesUCB S.A. - Pipeline Products GlanceUCB S.A. - Late Stage Pipeline ProductsPre-Registration Products/Combination Treatment ModalitiesPhase III Products/Combination Treatment ModalitiesUCB S.A. - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesPhase I Products/Combination Treatment ModalitiesUCB S.A. - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesDiscovery Products/Combination Treatment ModalitiesUCB S.A. - Drug ProfilesbrivaracetamProduct DescriptionMechanism of ActionR&D Progresscertolizumab pegolProduct DescriptionMechanism of ActionR&D ProgresslevetiracetamProduct DescriptionMechanism of ActionR&D ProgressepratuzumabProduct DescriptionMechanism of ActionR&D ProgresslacosamideProduct DescriptionMechanism of ActionR&D ProgressrotigotineProduct DescriptionMechanism of ActionR&D ProgressbimekizumabProduct DescriptionMechanism of ActionR&D Progressdapirolizumab pegolProduct DescriptionMechanism of ActionR&D ProgressUCB-0942Product DescriptionMechanism of ActionR&D ProgressUCB-5857Product DescriptionMechanism of ActionR&D ProgressUCB-7665Product DescriptionMechanism of ActionR&D ProgressAntibodies for Cancer, Immunology and InflammationProduct DescriptionMechanism of ActionR&D ProgressRecombinant Protein to Inhibit TNF-Alpha for Alzheimer's DiseaseProduct DescriptionMechanism of ActionR&D ProgressVR-942Product DescriptionMechanism of ActionR&D ProgressAntibodies for Diabetes and Metabolic DisordersProduct DescriptionMechanism of ActionR&D ProgressAntibody to Inhibit Transglutaminase 2 for FibrosisProduct DescriptionMechanism of ActionR&D ProgressUCB S.A. - Pipeline AnalysisUCB S.A. - Pipeline Products by TargetUCB S.A. - Pipeline Products by Route of AdministrationUCB S.A. - Pipeline Products by Molecule TypeUCB S.A. - Pipeline Products by Mechanism of ActionUCB S.A. - Recent Pipeline UpdatesUCB S.A. - Dormant ProjectsUCB S.A. - Discontinued Pipeline ProductsDiscontinued Pipeline Product ProfilesCDP-323CDP-435CDP-484CDP-860lacosamideseletracetamUCB-2892WX-037WX-554UCB S.A. - Company StatementUCB S.A. - Locations And SubsidiariesHead OfficeOther Locations & SubsidiariesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimerList of TablesUCB S.A., Key InformationUCB S.A., Key FactsUCB S.A. - Pipeline by Indication, 2015UCB S.A. - Pipeline by Stage of Development, 2015UCB S.A. - Monotherapy Products in Pipeline, 2015UCB S.A. - Partnered Products in Pipeline, 2015UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2015UCB S.A. - Out-Licensed Products in Pipeline, 2015UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015UCB S.A. - Pre-Registration, 2015UCB S.A. - Phase III, 2015UCB S.A. - Phase II, 2015UCB S.A. - Phase I, 2015UCB S.A. - Preclinical, 2015UCB S.A. - Discovery, 2015UCB S.A. - Pipeline by Target, 2015UCB S.A. - Pipeline by Route of Administration, 2015UCB S.A. - Pipeline by Molecule Type, 2015UCB S.A. - Pipeline Products by Mechanism of Action, 2015UCB S.A. - Recent Pipeline Updates, 2015UCB S.A. - Dormant Developmental Projects,2015UCB S.A. - Discontinued Pipeline Products, 2015UCB S.A., SubsidiariesList of FiguresUCB S.A. - Pipeline by Top 10 Indication, 2015UCB S.A. - Pipeline by Stage of Development, 2015UCB S.A. - Monotherapy Products in Pipeline, 2015UCB S.A. - Partnered Products in Pipeline, 2015UCB S.A. - Out-Licensed Products in Pipeline, 2015UCB S.A. - Pipeline by Top 10 Target, 2015UCB S.A. - Pipeline by Top 10 Route of Administration, 2015UCB S.A. - Pipeline by Top 10 Molecule Type, 2015UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Companies Mentioned in this ReportUCB S.A.
This report does not have a press release associated with it









Order Today!

FORMAT: PDF 
$1,500  USD
LICENSE: Single User 
DELIVERY: By Email - 1 Business Day


























The Fast Market Research Advantage

Only the Best
            All of our research is sourced from the most trusted and established global analysts and consultancies
Client Focused
            From start-ups to multinationals, we focus on providing the right research to our diverse client base
Shop Securely
            Our US-based customer service team and eCommerce systems adhere to the highest data security standards
Industry-leading Customer Support
            Individualized assistance from our expert staff is never more than an email or phone call away




BEST PRICE GUARANTEE
We are committed to providing the best research at the lowest cost.  We will match any published price for the same report, guaranteed!



EASY ORDERING
Once you’ve found the right report, click ‘order now’ and complete the checkout process
using any major credit card, check or wire/bank transfer.Need multi-user or enterprise license pricing?  Contact us for a custom quote!
                  




About the Publisher
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

Publisher Details







Privacy Policy | Terms of Use | FLASHALERTS


Copyright &copy 2017 Fast Market Research, Inc.



















UCB S.A. - Product Pipeline Review - 2015 : ReportsnReports


























 



 Market Research Report 


Welcome Guest  |  
					Register/Login | 
					Contact Us | 
					About Us
  




+ 1 888 391 5441








Advanced Search










Home › 
                    
                        Pharmaceuticals › 
                     Report Detail 



 UCB S.A. - Product Pipeline Review - 2015





						Published:  April 2015
						No. of Pages: 90

Price 
							
Single User License: US $ 1500
Corporate User License: US $ 4500
  
							


















Report Description
Table of Contents
 

Inquire Before Buying 










Global Markets Direct's, ?UCB S.A. - Product Pipeline Review - 2015', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of UCB S.A.'s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the UCB S.A.'s pipeline productsReasons to buyEvaluate UCB S.A.'s strategic position with total access to detailed information on its product pipelineAssess the growth potential of UCB S.A. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the UCB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues





                               UCB S.A. - Product Pipeline Review - 2015                            


Table of ContentsTable of Contents 2List of Tables 5List of Figures 5UCB S.A. Snapshot 6UCB S.A. Overview 6Key Information 6Key Facts 6UCB S.A. - Research and Development Overview 7Key Therapeutic Areas 7UCB S.A. - Pipeline Review 10Pipeline Products by Stage of Development 10Pipeline Products - Monotherapy 11Pipeline Products - Partnered Products 12Partnered Products/Combination Treatment Modalities 13Pipeline Products - Out-Licensed Products 14Out-Licensed Products/Combination Treatment Modalities 15UCB S.A. - Pipeline Products Glance 16UCB S.A. - Late Stage Pipeline Products 16Pre-Registration Products/Combination Treatment Modalities 16Phase III Products/Combination Treatment Modalities 17UCB S.A. - Clinical Stage Pipeline Products 18Phase II Products/Combination Treatment Modalities 18Phase I Products/Combination Treatment Modalities 19UCB S.A. - Early Stage Pipeline Products 20Preclinical Products/Combination Treatment Modalities 20Discovery Products/Combination Treatment Modalities 21UCB S.A. - Drug Profiles 22brivaracetam 22Product Description 22Mechanism of Action 22R&D Progress 22certolizumab pegol 24Product Description 24Mechanism of Action 24R&D Progress 24levetiracetam 31Product Description 31Mechanism of Action 31R&D Progress 31epratuzumab 34Product Description 34Mechanism of Action 34R&D Progress 34lacosamide 39Product Description 39Mechanism of Action 39R&D Progress 39rotigotine 44Product Description 44Mechanism of Action 44R&D Progress 44bimekizumab 47Product Description 47Mechanism of Action 47R&D Progress 47dapirolizumab pegol 48Product Description 48Mechanism of Action 48R&D Progress 48UCB-0942 50Product Description 50Mechanism of Action 50R&D Progress 50UCB-5857 51Product Description 51Mechanism of Action 51R&D Progress 51UCB-7665 52Product Description 52Mechanism of Action 52R&D Progress 52Antibodies for Cancer, Immunology and Inflammation 53Product Description 53Mechanism of Action 53R&D Progress 53Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 54Product Description 54Mechanism of Action 54R&D Progress 54VR-942 55Product Description 55Mechanism of Action 55R&D Progress 55Antibodies for Diabetes and Metabolic Disorders 56Product Description 56Mechanism of Action 56R&D Progress 56Antibody to Inhibit Transglutaminase 2 for Fibrosis 57Product Description 57Mechanism of Action 57R&D Progress 57UCB S.A. - Pipeline Analysis 58UCB S.A. - Pipeline Products by Target 58UCB S.A. - Pipeline Products by Route of Administration 60UCB S.A. - Pipeline Products by Molecule Type 61UCB S.A. - Pipeline Products by Mechanism of Action 62UCB S.A. - Recent Pipeline Updates 63UCB S.A. - Dormant Projects 79UCB S.A. - Discontinued Pipeline Products 80Discontinued Pipeline Product Profiles 80CDP-323 80CDP-435 80CDP-484 81CDP-860 81lacosamide 81seletracetam 81UCB-2892 81WX-037 82WX-554 82UCB S.A. - Company Statement 83UCB S.A. - Locations And Subsidiaries 84Head Office 84Other Locations & Subsidiaries 84Appendix 89Methodology 89Coverage 89Secondary Research 89Primary Research 89Expert Panel Validation 89Contact Us 89Disclaimer 90List of TablesUCB S.A., Key Information 6UCB S.A., Key Facts 6UCB S.A. - Pipeline by Indication, 2015 9UCB S.A. - Pipeline by Stage of Development, 2015 10UCB S.A. - Monotherapy Products in Pipeline, 2015 11UCB S.A. - Partnered Products in Pipeline, 2015 12UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2015 13UCB S.A. - Out-Licensed Products in Pipeline, 2015 14UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15UCB S.A. - Pre-Registration, 2015 16UCB S.A. - Phase III, 2015 17UCB S.A. - Phase II, 2015 18UCB S.A. - Phase I, 2015 19UCB S.A. - Preclinical, 2015 20UCB S.A. - Discovery, 2015 21UCB S.A. - Pipeline by Target, 2015 59UCB S.A. - Pipeline by Route of Administration, 2015 60UCB S.A. - Pipeline by Molecule Type, 2015 61UCB S.A. - Pipeline Products by Mechanism of Action, 2015 62UCB S.A. - Recent Pipeline Updates, 2015 63UCB S.A. - Dormant Developmental Projects,2015 79UCB S.A. - Discontinued Pipeline Products, 2015 80UCB S.A., Subsidiaries 84List of FiguresUCB S.A. - Pipeline by Top 10 Indication, 2015 8UCB S.A. - Pipeline by Stage of Development, 2015 10UCB S.A. - Monotherapy Products in Pipeline, 2015 11UCB S.A. - Partnered Products in Pipeline, 2015 12UCB S.A. - Out-Licensed Products in Pipeline, 2015 14UCB S.A. - Pipeline by Top 10 Target, 2015 58UCB S.A. - Pipeline by Top 10 Route of Administration, 2015 60UCB S.A. - Pipeline by Top 10 Molecule Type, 2015 61UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 62




 

Published By: 
                            Global Markets Direct 

Product Code:
                            Global Markets Direct10963 







                        Did you find what you are/were looking for
                        ?
                        If not, read below and browse through other relevant pages for similar market research
                        reports OR get in touch with us through the form/contact info in your right navigation
                        panel and well share relevant market report titles for you to explore.
					


                            Related Reports:
                        





 Global Onychomycosis (Tinea Unguium) Drug Detailed Analysis Report 2017-2022						
						This report splits Onychomycosis (Tinea Unguium) Drug by Product Drug Form, by Product Usage Type. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022.

And this report mainly introduces volume and value marke...  
 2017-2022 United States Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% fro...  
 2017-2022 United States Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 201...  
 2017-2022 Philippines Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from ...  
 2017-2022 Philippines Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 ...  
 2017-2022 Malaysia Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 201...  
 2017-2022 Malaysia Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to ...  
 2017-2022 Japan Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 t...  
 2017-2022 Japan Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 202...  
 2017-2022 India Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 t...  









 







  
   



Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
                            
Upto 24 hrs - working days
Upto 48 hrs max - weekends and public holidays






Research Support / Custom Research
                    If this business study does not have the data and information analysis you need,
                    contact us with your research requirements. We explore available market research
                    reports to map your needs and share report titles with you. Alternatively, we can
                    also offer custom research that suits your budget and timelines. Share your information
                    requirements here.



                        Connect With Us





 









































Email: sales@reportsandreports.com
Call : + 1 888 391 5441 


 



Home
Category
Publisher
Country
Latest Reports
Markets
Discounted Reports
Upcoming Reports
Contact Us



Subscription Option



                                Using our subscription option, you get access to market research reports and industry data of  Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.


More about our Subscription option 




Report Alerts

Get Email alerts about market research reports from industries and publishers of
							your interest:







Please Enter a Valid Email ID
Thank you! You have successfully subscribed to our Report Alerts!






 







 Avail upto 25% Discount on below Publisher Reports.

Technavio
Azoth Analytics







					© 2017 ReportsnReports. All rights reserved. Disclamer. 
						Privacy Policy , Terms and Conditions
					| Our Market Research Blog | Sitemap

Feeds: RSS | Latest Reports













UCB S.A. - Product Pipeline Review - 2015

























 info@marketreportscenter.com
 +1-646-883-3044 (US) 24x7















LOGIN
SIGN UP














Facebook



Twitter



LinkedIn



Google +



MRC Blog



YouTube







UCB S.A. - Product Pipeline Review - 2015

Home >> Pharmaceuticals >> Global Markets Direct >> UCB S.A. - Product Pipeline Review - 2015



Report Details





UCB S.A. - Product Pipeline Review - 2015







SKU
GMDMAR221562


Category
Pharmaceuticals


Publisher
Global Markets Direct


Pages
90


Published
Apr-15





SKUGMDMAR221562
CategoryPharmaceuticals
PublisherGlobal Markets Direct
Pages90
Published OnApr-15

Request Discount
Pay by Wire/Invoice





Description
Table of Content
List of Figures
Request Sample




Description
UCB S.A. - Product Pipeline Review - 2015

Summary

Global Markets Directs, UCB S.A. - Product Pipeline Review - 2015, provides an overview of the UCB S.A.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of UCB S.A.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the UCB S.A.s pipeline products

Reasons to buy

- Evaluate UCB S.A.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of UCB S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the UCB S.A.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

News/Press Release

Precision Medicine: How the life science industry can improve outcomes through To achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option, researchers in drug R&D need to better understand and manage the reams of unstructured dat...Read More
Regenerative Medicine Market to Hit $53 billion by 2021 The current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021, as impact of Trump administration....Read More
7 Benefits of MicroneedlingMicroneedling: Hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your face....Read More



Table of Content
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
UCB S.A. Snapshot 6
UCB S.A. Overview 6
Key Information 6
Key Facts 6
UCB S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
UCB S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
UCB S.A. - Pipeline Products Glance 16
UCB S.A. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
UCB S.A. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
UCB S.A. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
UCB S.A. - Drug Profiles 22
brivaracetam 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
certolizumab pegol 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
levetiracetam 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
epratuzumab 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lacosamide 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotigotine 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
bimekizumab 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
dapirolizumab pegol 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
UCB-0942 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
UCB-5857 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
UCB-7665 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Antibodies for Cancer, Immunology and Inflammation 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VR-942 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antibodies for Diabetes and Metabolic Disorders 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antibody to Inhibit Transglutaminase 2 for Fibrosis 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
UCB S.A. - Pipeline Analysis 58
UCB S.A. - Pipeline Products by Target 58
UCB S.A. - Pipeline Products by Route of Administration 60
UCB S.A. - Pipeline Products by Molecule Type 61
UCB S.A. - Pipeline Products by Mechanism of Action 62
UCB S.A. - Recent Pipeline Updates 63
UCB S.A. - Dormant Projects 79
UCB S.A. - Discontinued Pipeline Products 80
Discontinued Pipeline Product Profiles 80
CDP-323 80
CDP-435 80
CDP-484 81
CDP-860 81
lacosamide 81
seletracetam 81
UCB-2892 81
WX-037 82
WX-554 82
UCB S.A. - Company Statement 83
UCB S.A. - Locations And Subsidiaries 84
Head Office 84
Other Locations & Subsidiaries 84
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90


List of Figures
List of Tables
UCB S.A., Key Information 6
UCB S.A., Key Facts 6
UCB S.A. - Pipeline by Indication, 2015 9
UCB S.A. - Pipeline by Stage of Development, 2015 10
UCB S.A. - Monotherapy Products in Pipeline, 2015 11
UCB S.A. - Partnered Products in Pipeline, 2015 12
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2015 13
UCB S.A. - Out-Licensed Products in Pipeline, 2015 14
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
UCB S.A. - Pre-Registration, 2015 16
UCB S.A. - Phase III, 2015 17
UCB S.A. - Phase II, 2015 18
UCB S.A. - Phase I, 2015 19
UCB S.A. - Preclinical, 2015 20
UCB S.A. - Discovery, 2015 21
UCB S.A. - Pipeline by Target, 2015 59
UCB S.A. - Pipeline by Route of Administration, 2015 60
UCB S.A. - Pipeline by Molecule Type, 2015 61
UCB S.A. - Pipeline Products by Mechanism of Action, 2015 62
UCB S.A. - Recent Pipeline Updates, 2015 63
UCB S.A. - Dormant Developmental Projects,2015 79
UCB S.A. - Discontinued Pipeline Products, 2015 80
UCB S.A., Subsidiaries 84
List of Figures
UCB S.A. - Pipeline by Top 10 Indication, 2015 8
UCB S.A. - Pipeline by Stage of Development, 2015 10
UCB S.A. - Monotherapy Products in Pipeline, 2015 11
UCB S.A. - Partnered Products in Pipeline, 2015 12
UCB S.A. - Out-Licensed Products in Pipeline, 2015 14
UCB S.A. - Pipeline by Top 10 Target, 2015 58
UCB S.A. - Pipeline by Top 10 Route of Administration, 2015 60
UCB S.A. - Pipeline by Top 10 Molecule Type, 2015 61
UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 62







Please Select License Type






Single User Electronic PDF 
$ 1,500.00


Site User Electronic PDF 
$ 3,000.00


Enterprise Wide Electronic PDF 
$ 4,500.00



ADD TO CART

BUY NOW






Related Reports




 Lighting Product Markets in the Top 5 American Countries to 2021 Lighting Product Markets in the Top 5 Asian Countries to 2021 Lighting Product Markets in the Top 5 European Countries to 2021 Global Lighting Product Market to 2021 Lighting Product Markets in Africa to 2021 










Request Sample






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Request Discount






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Pay by Wire/Invoice






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
















Single User Electronic PDF
Site User Electronic PDF
Enterprise Wide Electronic PDF
CD ROM
Hard Copy














SEND










Request Quote






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND









Market Reports Center © Copyright 2017 All rights reserved.









































UCB S.A. - Product Pipeline Review - 2014 : ReportsnReports


























 



 Market Research Report 


Welcome Guest  |  
					Register/Login | 
					Contact Us | 
					About Us
  




+ 1 888 391 5441








Advanced Search










Home › 
                    
                        Pharmaceuticals › 
                     Report Detail 



 UCB S.A. - Product Pipeline Review - 2014





						Published:  June 2014
						No. of Pages: 87

Price 
							
Single User License: US $ 1500
Corporate User License: US $ 4500
  
							


















Report Description
Table of Contents
 

Inquire Before Buying 










Global Markets Direct's, ?UCB S.A. Product Pipeline Review 2014', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of UCB S.A.'s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the UCB S.A.'s pipeline productsReasons to buyEvaluate UCB S.A.'s strategic position with total access to detailed information on its product pipelineAssess the growth potential of UCB S.A. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the UCB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues





                               UCB S.A. - Product Pipeline Review - 2014                            


Table of ContentsTable of Contents 2List of Tables 5List of Figures 5UCB S.A. Snapshot 6UCB S.A. Overview 6Key Information 6Key Facts 6UCB S.A. - Research and Development Overview 7Key Therapeutic Areas 7UCB S.A. - Pipeline Review 10Pipeline Products by Stage of Development 10Pipeline Products - Monotherapy 11Pipeline Products - Partnered Products 12Partnered Products/Combination Treatment Modalities 13Pipeline Products - Out-Licensed Products 14Out-Licensed Products/Combination Treatment Modalities 15UCB S.A. - Pipeline Products Glance 16UCB S.A. - Late Stage Pipeline Products 16Pre-Registration Products/Combination Treatment Modalities 16Filing rejected/Withdrawn Products/Combination Treatment Modalities 17Phase III Products/Combination Treatment Modalities 18UCB S.A. - Clinical Stage Pipeline Products 19Phase II Products/Combination Treatment Modalities 19Phase I Products/Combination Treatment Modalities 20UCB S.A. - Early Stage Pipeline Products 21Preclinical Products/Combination Treatment Modalities 21Discovery Products/Combination Treatment Modalities 22UCB S.A. - Drug Profiles 23lacosamide 23Product Description 23Mechanism of Action 23R&D Progress 23levetiracetam 27Product Description 27Mechanism of Action 27R&D Progress 27certolizumab pegol 30Product Description 30Mechanism of Action 30R&D Progress 30brivaracetam 36Product Description 36Mechanism of Action 36R&D Progress 36epratuzumab 38Product Description 38Mechanism of Action 38R&D Progress 38rotigotine 43Product Description 43Mechanism of Action 43R&D Progress 43UCB-4940 46Product Description 46Mechanism of Action 46R&D Progress 46CDP-7657 47Product Description 47Mechanism of Action 47R&D Progress 47UCB-5857 49Product Description 49Mechanism of Action 49R&D Progress 49Antibody for Cancer, Immunology and Inflammation 50Product Description 50Mechanism of Action 50R&D Progress 50VR-942 51Product Description 51Mechanism of Action 51R&D Progress 51Humanized Transglutaminase 2 Inhibitory Antibody 52Product Description 52Mechanism of Action 52R&D Progress 52UCB S.A. - Pipeline Analysis 53UCB S.A. - Pipeline Products by Target 53UCB S.A. - Pipeline Products by Route of Administration 55UCB S.A. - Pipeline Products by Molecule Type 56UCB S.A. - Pipeline Products by Mechanism of Action 57UCB S.A. - Recent Pipeline Updates 59UCB S.A. - Dormant Projects 76UCB S.A. - Discontinued Pipeline Products 78Discontinued Pipeline Product Profiles 78CDP-323 78CDP-435 78CDP-484 78CDP-571 79CDP-860 79lacosamide 79seletracetam 79UCB-0942 79UCB-2892 80UCB S.A. - Company Statement 81UCB S.A. - Locations And Subsidiaries 82Head Office 82Other Locations & Subsidiaries 82Appendix 86Methodology 86Coverage 86Secondary Research 86Primary Research 86Expert Panel Validation 86Contact Us 87Disclaimer 87List of TablesUCB S.A., Key Information 6UCB S.A., Key Facts 6UCB S.A. - Pipeline by Indication, 2014 9UCB S.A. - Pipeline by Stage of Development, 2014 10UCB S.A. - Monotherapy Products in Pipeline, 2014 11UCB S.A. - Partnered Products in Pipeline, 2014 12UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2014 13UCB S.A. - Out-Licensed Products in Pipeline, 2014 14UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2014 15UCB S.A. - Pre-Registration, 2014 16UCB S.A. - Filing rejected/Withdrawn, 2014 17UCB S.A. - Phase III, 2014 18UCB S.A. - Phase II, 2014 19UCB S.A. - Phase I, 2014 20UCB S.A. - Preclinical, 2014 21UCB S.A. - Discovery, 2014 22UCB S.A. - Pipeline by Target, 2014 54UCB S.A. - Pipeline by Route of Administration, 2014 55UCB S.A. - Pipeline by Molecule Type, 2014 56UCB S.A. - Pipeline Products by Mechanism of Action, 2014 58UCB S.A. - Recent Pipeline Updates, 2014 59UCB S.A. - Dormant Developmental Projects,2014 76UCB S.A. - Discontinued Pipeline Products, 2014 78UCB S.A., Subsidiaries 82List of FiguresUCB S.A. - Pipeline by Top 10 Indication, 2014 8UCB S.A. - Pipeline by Stage of Development, 2014 10UCB S.A. - Monotherapy Products in Pipeline, 2014 11UCB S.A. - Partnered Products in Pipeline, 2014 12UCB S.A. - Pipeline by Top 10 Target, 2014 53UCB S.A. - Pipeline by Top 10 Route of Administration, 2014 55UCB S.A. - Pipeline by Top 10 Molecule Type, 2014 56UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014 57




 

Published By: 
                            Global Markets Direct 

Product Code:
                            Global Markets Direct8738 







                        Did you find what you are/were looking for
                        ?
                        If not, read below and browse through other relevant pages for similar market research
                        reports OR get in touch with us through the form/contact info in your right navigation
                        panel and well share relevant market report titles for you to explore.
					


                            Related Reports:
                        





 Global Onychomycosis (Tinea Unguium) Drug Detailed Analysis Report 2017-2022						
						This report splits Onychomycosis (Tinea Unguium) Drug by Product Drug Form, by Product Usage Type. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022.

And this report mainly introduces volume and value marke...  
 2017-2022 United States Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% fro...  
 2017-2022 United States Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 201...  
 2017-2022 Philippines Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from ...  
 2017-2022 Philippines Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 ...  
 2017-2022 Malaysia Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 201...  
 2017-2022 Malaysia Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in Malaysia, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to ...  
 2017-2022 Japan Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 t...  
 2017-2022 Japan Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 202...  
 2017-2022 India Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 t...  









 







  
   



Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
                            
Upto 24 hrs - working days
Upto 48 hrs max - weekends and public holidays






Research Support / Custom Research
                    If this business study does not have the data and information analysis you need,
                    contact us with your research requirements. We explore available market research
                    reports to map your needs and share report titles with you. Alternatively, we can
                    also offer custom research that suits your budget and timelines. Share your information
                    requirements here.



                        Connect With Us





 









































Email: sales@reportsandreports.com
Call : + 1 888 391 5441 


 



Home
Category
Publisher
Country
Latest Reports
Markets
Discounted Reports
Upcoming Reports
Contact Us



Subscription Option



                                Using our subscription option, you get access to market research reports and industry data of  Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.


More about our Subscription option 




Report Alerts

Get Email alerts about market research reports from industries and publishers of
							your interest:







Please Enter a Valid Email ID
Thank you! You have successfully subscribed to our Report Alerts!






 







 Avail upto 25% Discount on below Publisher Reports.

Technavio
Azoth Analytics







					© 2017 ReportsnReports. All rights reserved. Disclamer. 
						Privacy Policy , Terms and Conditions
					| Our Market Research Blog | Sitemap

Feeds: RSS | Latest Reports








